The U.S. Department of Health and Human Services awarded Tempus AI a $60 million ARPA‑H contract to support testing and research using biomarkers to create adaptive treatment strategies for cancer. The program will pair clinical testing with computational models to inform personalized, biomarker‑driven interventions. Tempus will provide testing services and analytics capacity; government funding signals federal interest in data‑driven, adaptive oncology trials. The award positions Tempus to expand its clinical research footprint and to supply trial infrastructures that rely on rapid biomarker readouts and AI‑derived treatment recommendations.